Your Messages Inbox
Your Article Summary
See Latest ArticlesFDA Approves Besivance to Treat Bacterial Conjunctivitis
FDA Press Releases , 05/29/09
The U.S. Food and Drug Administration today approved Besivance for the treatment of bacterial conjunctivitis, a contagious condition marked by irritation of the eyes and a discharge from the mucous membranes. "Bacterial conjunctivitis is a common condition that affects people of all ages," said Wiley A. Chambers, M.D., acting director of the Division of Anti-Infective and Ophthalmology Products in FDA's Center for Drug Evaluation and Research. "It is important to have a variety of treatment options available to health care professionals and patients because an effective drug therapy can reduce the duration of the illness and reduce the chances of infecting others."
Related Articles
Successful treatment of ligneous conjunctivitis with topical cyclosporine and heparin
Journal of American Association for Pediatric Ophthalmology and Strabismus, 11/03/09
Relevance Score: 88%
Evidence-based treatment of acute infective conjunctivitis: Breaking the cycle of antibiotic prescribing
Canadian Family Physician, 11/13/09
Relevance Score: 87%
Effect of oral azithromycin in the treatment of chlamydial conjunctivitis
Eye, 11/09/09
Relevance Score: 85%
Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children
Clinical Therapeutics, 10/29/09
Relevance Score: 85%
Relationship between myopia and allergen-specific serum IgE levels in patients with allergic conjunctivitis
Clinical and Experimental Ophthalmology, 10/09/09
Relevance Score: 84%
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD
Novartis, 12/04/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Bayer's Betaferon approved in China for Treatment of Multiple Sclerosis
BayNews International, 12/02/09
Article Search
Sponsor